Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expires

Natco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the innovator's drug. The company aims to make this treatment more accessible to patients across India. Other pharmaceutical companies are also preparing to launch their generic versions. This development promises significant cost savings for consumers seeking this medication.